Top

Cellular Oncology

Published in:

01-10-2012 | Original Paper

Chlorophyllin abrogates canonical Wnt/β-catenin signaling and angiogenesis to inhibit the development of DMBA-induced hamster cheek pouch carcinomas

Authors: Nagini Siddavaram, Vidya Priyadarsini Ramamurthi, Veeravarmal Veeran, Rajakishore Mishra

Published in: Cellular Oncology | Issue 5/2012

Abstract

Background

Chlorophyllin, a water soluble semi-synthetic food-grade derivative is reported to exhibit a wide range of beneficial health effects. We investigated the effect of chlorophyllin supplementation on Wnt/β-catenin and vascular endothelial growth factor (VEGF) signaling in the 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster buccal pouch (HBP) carcinogenesis model.

Methods and results

Hamsters were divided into 4 groups. The right buccal pouches of group 1 and 2 hamsters were painted with 0.5 % DMBA for 14 weeks. Group 2 animals received in addition chlorophyllin (4 mg/kg bw) in the diet. Group 3 animals received chlorophyllin alone and group 4 animals served as control. mRNA and protein expression of components of Wnt, VEGF, and PI3K/Akt signaling pathways were analyzed by RT-PCR and Western blot analysis. Dietary chlorophyllin administration suppressed the development of HBP carcinomas by altering the expression of several components of the Wnt/β-catenin signaling pathway. This was associated with inhibition of angiogenesis as evidenced by decreased expression of the proangiogenic factors HIF-1α, VEGF, and VEGFR2. Chlorophyllin administration also downregulated the expression of histone deacetylases involved in epigenetic regulation of tumor angiogenesis.

Conclusion

Dietary chlorophyllin that abrogates Wnt/β-catenin and VEGF signaling by targeting a multitude of key signaling molecules is an attractive candidate for preventing tumor progression.

R. Dashwood, Chlorophylls as anticarcinogens. Int. J. Oncol. 10, 721–727 (1997)PubMed

R. Dashwood, T. Negishi, H. Hayatsu, V. Breinholt, J. Hendricks, G. Bailey, Chemopreventive properties of chlorophylls towards aflatoxin B1: a review of the antimutagenicity and anticarcinogenicity data in rainbow trout. Mutat. Res. 399, 245–253 (1998)PubMedCrossRef

L.C. Chiu, C.K. Kong, V.E. Ooi, The chlorophyllin-induced cell cycle arrest and apoptosis in human breast cancer MCF-7 cells is associated with ERK deactivation and cyclin D1 depletion. Int. J. Mol. Med. 16, 735–740 (2005)PubMed

K. Chimploy, G.D. Diaz, Q. Li, O. Carter, W.M. Dashwood, C.K. Mathews, D.E. Williams, G.S. Bailey, R.H. Dashwood, E2F4 and ribonucleotide reductase mediate S phase arrest in colon cancer cells treated with chlorophyllin. Int. J. Cancer 125, 2086–2094 (2009)PubMedCrossRef

X.W. Ding, X.L. Ding, S. Zheng, H.J. Yang, CHL prevent colon neoplasms in mice and its selective inhibition on COX-2. Ai Zheng 23, 1409–1413 (2004)PubMed

M.T. Simonich, T. McQuistan, C. Jubert, C. Pereira, J.D. Hendricks, M. Schimerlik, B. Zhu, R.H. Dashwood, D.E. Williams, G.S. Bailey, Low-dose dietary chlorophyll inhibits multi-organ carcinogenesis in the rainbow trout. Food Chem. Toxicol. 46, 1014–1024 (2008)PubMedCrossRef

A.P. Reddy, U. Harttig, M.C. Barth, W.M. Baird, M. Schimerlik, J.D. Hendricks, G.S. Bailey, Inhibition of dibenzo[a, l]pyrene-induced multi-organ carcinogenesis by dietary chlorophyllin in rainbow trout. Carcinogenesis 20, 1919–1926 (1999)PubMedCrossRef

P. Thiyagarajan, R. Senthil Murugan, K. Kavitha, P. Anitha, D. Prathiba, S. Nagini, Dietary chlorophyllin inhibits the canonical NF-κB signaling pathway and induces intrinsic apoptosis in a hamster model of oral oncogenesis. Food Chem. Toxicol. 50, 867–876 (2012)PubMedCrossRef

D.T. Shaughnessy, L.M. Gangarosa, B. Schliebe, D.M. Umbach, Z. Xu, B. MacIntosh, M.G. Knize, P.P. Matthews, A.E. Swank, R.S. Sandler, D.M. DeMarini, J.A. Taylor, Inhibition of fried meat-induced colorectal DNA damage and altered systemic genotoxicity in humans by crucifera, chlorophyllin, and yogurt. PLoS One 6, e18707 (2011)PubMedCrossRef

10.

P.A. Egner, J.B. Wang, Y.R. Zhu, B.C. Zhang, Y. Wu, Chlorophyllin intervention reduces aflatoxin–DNA adducts in individuals at high risk for liver cancer. Proc. Natl. Acad. Sci. USA 98, 14601–14606 (2001)PubMedCrossRef

11.

J.P. Kamat, K.K. Boloor, T.P. Devasagayam, Chlorophyllin as an effective antioxidant against membrane damage in vitro and ex vivo. Biochim. Biophys. Acta 1487, 113–127 (2000)PubMedCrossRef

12.

S. Arimoto, S. Fukuoka, C. Itome, H. Nakano, H. Rai, H. Hayatsu, Binding of polycyclic planar mutagens to chlorophyllin resulting in inhibition of the mutagenic activity. Mutat. Res. 287, 293–305 (1993)PubMedCrossRef

13.

M. Hirose, A. Nishikawa, M. Shibutani, T. Imai, T. Shirai, Chemoprevention of heterocyclic amine-induced mammary carcinogenesis in rats. Environ. Mol. Mutagen. 39, 271–278 (2002)PubMedCrossRef

14.

V. Breinholt, M. Schimerlik, R. Dashwood, G. Bailey, Mechanisms of chlorophyllin anticarcinogenesis against aflatoxin B1: complex formation with the carcinogen. Chem. Res. Toxicol. 8, 506–514 (1995)PubMedCrossRef

15.

K. John, R.L. Divi, C. Keshava, C.C. Orozco, M.E. Schockley, D.L. Richardson, M.C. Poirier, J. Nath, A. Weston, CYP1A1 and CYP1B1 gene expression and DNA adduct formation in normal human mammary epithelial cells exposed to benzo[a]pyrene in the absence or presence of chlorophyllin. Cancer Lett. 292, 254–260 (2010)PubMedCrossRef

16.

Y. Zhang, L. Guan, X. Wang, T. Wen, J. Xing, J. Zhao, Protection of chlorophyllin against oxidative damage by inducing HO-1 and NQO1 expression mediated by PI3K/Akt and Nrf2. Free. Radic. Res. 42, 362–371 (2008)PubMedCrossRef

17.

N. Tachino, D. Guo, W.M. Dashwood, S. Yamane, R. Larsen, R. Dashwood, Mechanisms of the in vitro antimutagenic action of chlorophyllin against benzo[a]pyrene: studies of enzyme inhibition, molecular complex formation and degradation of the ultimate carcinogen. Mutat. Res. 308, 191–203 (1994)PubMedCrossRef

18.

G.D. Diaz, Q. Li, R.H. Dashwood, Caspase-8 and apoptosis-inducing factor mediate a cytochrome c-independent pathway of apoptosis in human colon cancer cells induced by the dietary phytochemical chlorophyllin. Cancer Res. 63, 1254–1261 (2003)PubMed

19.

M.S. Khan, D. Halagowder, S.N. Devaraj, Methylated chrysin induces co-ordinated attenuation of the canonical Wnt and NF-κB signaling pathway and upregulates apoptotic gene expression in the early hepatocarcinogenesis rat model. Chem. Biol. Interact. 193, 12–21 (2011)PubMedCrossRef

20.

S. Huang, C.A. Pettaway, H. Uehara, C.D. Bucana, I.J. Fidler, Blockade of NfkappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20, 4188–4197 (2001)PubMedCrossRef

21.

H.L. Pahl, Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18, 6853–6866 (1999)PubMedCrossRef

22.

R.S. Tarapore, I.A. Siddiqui, H. Mukhtar, Modulation of Wnt/β-catenin signalling pathway by bioactive food components. Carcinogenesis 33, 483–491 (2012)PubMedCrossRef

23.

R. Jr, Roskoski, Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit. Rev. Oncol. Hematol. 62, 179–213 (2007)CrossRef

24.

A. Surazynski, P. Steven, S.P. Donald, K. Sandra, S.K. Cooper, M.A. Whiteside, K. Salnikow, Y. Liu, J.M. Phang, Extracellular matrix and HIF-1 signaling: the role of prolidase. Int. J. Cancer 22, 1435–1440 (2008)

25.

H.P. Gerber, A. McMurtrey, J. Kowalski, M. Yan, B.A. Keyt, V. Dixit, N. Ferrara, Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273, 30336–30343 (1998)PubMedCrossRef

26.

I.H. Koumakpayi, C. Le Page, A.M. Mes-Masson, F. Saad, Hierarchical clustering of immunohistochemical analysis of the activated erbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer. Br. J. Cancer 102, 1163–1173 (2010)PubMedCrossRef

27.

O. Witt, H.E. Deubzer, T. Milde, I. Oehme, HDAC family: what are the cancer relevant targets? Cancer Lett. 77, 8–21 (2009)CrossRef

28.

G. Shklar, Development of experimental oral carcinogenesis and its impact on current oral cancer research. J. Dent. Res. 78, 1768–1772 (1999)PubMedCrossRef

29.

E. Madrigal-Bujaidar, N. Velazquez-Guadarrama, S. Diaz-Barriga, Inhibitory effect of chlorophyllin on the frequency of sister chromatid exchanges produced by benzo[a]pyrene in vivo. Mutat. Res. 388, 79–83 (1997)PubMedCrossRef

30.

S. Nagini, P. Vidjaya Letchoumy, A. Thangavelu, R. Cr, Of humans and hamsters: a comparative evaluation of carcinogen activation, DNA damage, cell proliferation, apoptosis, invasion, and angiogenesis in oral cancer patients and hamster buccal pouch carcinomas. Oral. Oncol. 45, e31–e37 (2009)PubMedCrossRef

31.

M.M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254 (1976)PubMedCrossRef

32.

S. Legrand-Poels, S. Schoonbrodt, J. Piette, Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line. Biochem. J. 349, 765–773 (2000)PubMed

33.

Y. Fu, S. Zheng, N. An, T. Athanasopoulos, L. Popplewell, A. Liang, K. Li, C. Hu, Y. Zhu, β-catenin as a potential key target for tumor suppression. Int. J. Cancer 129, 1541–1551 (2011)PubMedCrossRef

34.

A. Bafico, G. Liu, L. Goldin, V. Harris, S.A. Aaronson, An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell. 6, 497–506 (2004)PubMedCrossRef

35.

R. Najdi, R.F. Holcombe, M.L. Waterman, Wnt signaling and colon carcinogenesis: beyond APC. J. Carcinog. 10, 5 (2011)PubMedCrossRef

36.

C. Gaston-Massuet, C.L. Andoniadou, M. Signore, S.A. Jayakody, N. Charolidi, R. Kyeyune, B. Vernay, T.S. Jacques, M.M. Taketo, P. Le Tissier, M.T. Dattani, J.P. Martinez-Barbera, Increased wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans. Nutr. Cancer 63, 558–564 (2011)CrossRef

37.

L. Queimado, D. Obeso, M.D. Hatfield, Y. Yang, D.M. Thompson, A.M. Reis, Dysregulation of Wnt pathway components in human salivary gland tumors. Arch. Otolaryngol. Head Neck Surg. 134, 94–101 (2008)PubMedCrossRef

38.

I. Gehrke, R.K. Gandhirajan, K.A. Kreuzer, Targeting the WNT/b-catenin/TCF/LEF1 axis in solid and haematological cancers: multiplicity of therapeutic options. Eur. J. Cancer 45, 2759–2767 (2009)PubMedCrossRef

39.

R. Vidya Priyadarsini, R. Senthil Murugan, S. Nagini, Aberrant activation of Wnt/β-catenin signaling pathway contributes to the sequential progression of DMBA induced HBP carcinomas. Oral Oncol. 48, 33–39 (2012)PubMedCrossRef

40.

J.K. Sethi, A. Vidal-Puig, Wnt signalling and the control of cellular metabolism. Biochem. J. 427, 1–17 (2010)PubMedCrossRef

41.

B.W. Doble, J.R. Woodgett, GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell. Sci. 116, 1175–1186 (2003)PubMedCrossRef

42.

R. Mishra, Gliycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol. Cancer 9, 144 (2010)PubMedCrossRef

43.

J. Luo, Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett. 273, 194–200 (2009)PubMedCrossRef

44.

O. Carter, G.S. Bailey, R.H. Dashwood, The dietary phytochemical chlorophyllin alters E-cadherin and beta-catenin expression in human colon cancer cells. J. Nutr. 134, 3441–344 (2004)

45.

S. Song, N. Mazurek, C. Liu, Y. Sun, Q.Q. Ding, K. Liu, M.C. Hung, R.S. Bresalier, Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res. 69, 1343–1349 (2009)PubMedCrossRef

46.

A. Iamaroon, S. Krisanaprakornkit, Overexpression and activation of Akt2 protein in oral squamous cell carcinoma. Oral Oncol. 45, e175–e179 (2009)PubMedCrossRef

47.

J.A. Morrison, M.L. Gulley, R. Pathmanathan, N. Raab-Traub, Differential signalling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res. 64, 5251–5260 (2004)PubMedCrossRef

48.

K.H. Chun, H.Y. Lee, K. Hassan, F. Khuri, W.K. Hong, R. Lotan, Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res. 63, 4796–4800 (2003)PubMed

49.

P. Amornphimoltham, V. Sriuranpong, V. Patel, F. Benavides, C.J. Conti, J. Sauk, E.A. Sausville, A.A. Molinolo, J.S. Gutkind, Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin. Cancer Res. 10, 4029–4037 (2004)PubMedCrossRef

50.

Y. Li, Z. Wang, D. Kong, R. Li, S.H. Sarkar, F.H. Sarkar, Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells. J. Biol. Chem. 283, 27707–27716 (2008)PubMedCrossRef

51.

P. Roy, N. Kalra, S. Prasad, J. George, Y. Shukla, Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharm. Res. 26, 211–217 (2009)PubMedCrossRef

52.

C. Hope, K. Planutis, M. Planutiene, M.P. Moyer, K.S. Johal, J. Woo, C. Santoso, J.A. Hanson, R.F. Holcombe, Low concentrations of resveratrol inhibit Wnt signal throughput in colon-derived cells: implications for colon cancer prevention. Mol. Nutr. Food Res. 52, S52–S61 (2008)PubMed

53.

M. Potente, H. Gerhardt, P. Carmeliet, Basic and therapeutic aspects of angiogenesis. Cell 146, 873–887 (2011)PubMedCrossRef

54.

X. Lu, Y. Kang, Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin. Cancer Res. 16, 5928–5935 (2011)CrossRef

55.

L. Ellis, H. Hammers, R. Pili, Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 280, 145–153 (2009)PubMedCrossRef

56.

D.Z. Qian, S.K. Kachhap, S.J. Collis, H.M. Verheul, M.A. Carducci, P. Atadja, R. Pili, Class II histone deacetylases are associated with VHL independent regulation of hypoxia-inducible factor 1α. Cancer Res. 66, 668814–668821 (2006)

57.

P. Anitha, R. Vidya Priyadarsini, K. Kavitha, P. Thiyagarajan, S. Nagini, Ellagic acid coordinately attenuates Wnt/β-catenin and NF-κB signaling pathways to induce intrinsic apoptosis in an animal model of oral oncogenesis. Eur. J. Nutr. (2012).

58.

T.A. Bhat, R.P. Singh, Tumor angiogenesis—a potential target in cancer chemoprevention. Food Chem. Toxicol. 6, 1334–1345 (2008)

Title: Chlorophyllin abrogates canonical Wnt/β-catenin signaling and angiogenesis to inhibit the development of DMBA-induced hamster cheek pouch carcinomas
Authors: Nagini Siddavaram
Vidya Priyadarsini Ramamurthi
Veeravarmal Veeran
Rajakishore Mishra
Publication date: 01-10-2012
Publisher: Springer Netherlands
Published in: Cellular Oncology / Issue 5/2012
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-012-0099-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods and results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2012

Prognostic value of CD44 expression in penile squamous cell carcinoma: a pilot study

Aberrant microRNA expression and its implications in the pathogenesis of leukemias

Skewed immunological balance between Th17 (CD4+IL17A+) and Treg (CD4+CD25+FOXP3+) cells in human oral squamous cell carcinoma

Identification of a novel short peptide seal specific to CD59 and its effect on HeLa cell growth and apoptosis

Molecular diagnosis of minimal residual disease in head and neck cancer patients

Colon cancer cells expressing cell surface GRP78 as a marker for reduced tumorigenicity

Keynote webinar | Spotlight on antibody–drug conjugates in cancer